Semaglutide versus other GLP-1 RAs and cardiovascular risk in obesity-related cancer survivors

Diabetes research and clinical practice · 2026 Oct 29 · Abdelgadir O, Hernández-Pérez JG, Hussain MR et

By Maren Holt · Senior Reporter, GLP-1

Oct 28 20:00 ETSource: Diabetes research and clinical practice

From the source

Semaglutide versus other GLP-1 RAs and cardiovascular risk in obesity-related cancer survivors
Diabetes research and clinical practice · 2026 Oct 29 · Abdelgadir O, Hernández-Pérez JG, Hussain MR et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42956842/